Piramal Pharma: Record Growth and New Expansion Plans Revealed!

Piramal Pharma: Record Growth and New Expansion Plans Revealed!

Mumbai, India (ots/PRNewswire)

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635) is making a strong statement in the pharmaceutical industry! The company today reported its impressive second quarter (Q2) and first half (HY1) results ended September 30, 2024. With a record turnover of₹2,242 Crorein Q2, which represents an astonishing increase of17%compared to the previous year, as well as a total turnover of₹4,193 Crorefor the first half of the year, the company leaves the competition behind! These figures reflect remarkably strong growth in the contract development and manufacturing organization (CDMO) sector, with aGrowth of 24%shines.

Powerful performance and sustainable initiatives

But that's not all! EBITDA rose sharply28%on₹403 Crorein Q2, causing the EBITDA margin to increase18%increased, an improvement of 150 basis points. “We see our commitment to sustainability continuing to grow,” saidNandini Piramal, Chairman of Piramal Pharma Limited, and proudly announced the company's new sustainability report that is in line with GRI standards. It emphasizes the company's responsibility to reduce greenhouse gas emissions and shows that Pirate Pharma wants to create a sustainable future!

The company is also focusing on significant expansions! With an ambitious one$80 million planto expand production capacity in Lexington, paving the way for further growth. Capacity expansion is well underway in the Hospital Generics (CHG) and India Consumer Healthcare (ICH) sectors. Orders continue to rise and demand for innovative products reaches new heights. Piramal Pharma is bulking up for the challenges of the future!

OnOctober 24, 2024The company will hold a conference call for investors and analysts to discuss the results in detail. The rise of Piramal Pharma does not go unnoticed and shows that innovation and growth are linked.